Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.

Core Insights - BioPorto A/S reported continued progress on key strategic milestones in Q1 2025, maintaining revenue guidance for the year [1][2] - The company experienced a 19% decrease in revenue compared to Q1 2024, totaling DKK 7.7 million, primarily due to a shift in timing of bulk orders [5][7] - Adjusted EBITDA loss increased by 83% to DKK 28.1 million, driven by higher costs associated with clinical studies [5][7] Financial Performance - Revenue for Q1 2025 was DKK 7.7 million, down from DKK 9.5 million in Q1 2024, reflecting a 19% decline [5][7] - The adjusted EBITDA loss for Q1 2025 was DKK 28.1 million, compared to DKK 15.3 million in the same period last year, marking an 83% increase [5][7] - Full-year revenue guidance for 2025 remains at DKK 45-60 million, with expectations of back-end loaded sales [7] Sales and Market Developments - NGAL Research Use Only (RUO) sales in the U.S. grew by 20% compared to Q1 2024, despite a 25% decline in total NGAL sales due to decreased sales in the rest of the world [6][7] - Preparations for the commercial launch of ProNephro AKI NGAL for pediatric use are on track, with faster-than-expected patient enrollment in the adult clinical study [6][7] - The company aims to submit to the FDA by the end of 2026 for the ProNephro AKI (NGAL) study [6][7] Capital and Investment - On April 16, 2025, BioPorto completed a successful issuance of 25,000,000 new shares, raising gross proceeds of DKK 33.5 million [4][8] - The funding round attracted strong commitments from both existing shareholders and new investors [4]